Skip to main content
2026 search results for:

Exenatide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-05-2024 | Linagliptin | News

    Exenatide/linagliptin

    Atrial fibrillation and lack of efficacy
  2. 01-04-2024 | Exenatide | News

    Exenatide/liraglutide/semaglutide

    Suicidal behaviour and suicidal attempt
  3. 01-04-2024 | Insulins | News

    Exenatide/insulin-detemir/insulin-glargine/insulin-lispro/metformin

    Lipohypertrophy and GERD-like side effects
  4. Open Access 02-04-2024 | Exenatide | Online First

    Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial

    Alzheimer’s disease (AD) represents the most common chronic neurodegenerative disorder, accounting for ~ 60–70% of all forms of dementia [ 1 ]. AD has a global overall prevalence of 3.9% in people ≥ 60 years [ 2 ] with over 43.8 million people …

  5. 31-08-2023 | Exenatide | OriginalPaper

    Early effect of exenatide treatment on atherogenicity in patients with type 2 diabetes mellitus

    It is estimated that 450 million individuals worldwide have type 2 diabetes mellitus (T2DM), and by the year 2040, that number will rise to 640 million [ 1 ]. The close relationship of T2DM with insulin resistance and obesity has brought a new …

  6. 14-04-2023 | Obesity | OriginalPaper

    Free T4 is associated with exenatide-related weight loss in patients with type 2 diabetes mellitus and obesity

    Obesity is a frequent co-existing condition in the patients with type 2 diabetes. In one study, 59% of the patients with type 2 diabetes did have obesity, 31% were overweight [ 1 ]. Hence, antidiabetic medications providing weight loss has come …

  7. Open Access 01-12-2023 | Obesity | OriginalPaper

    The first successful desensitization protocol in exenatide allergy: a case report

    Glucagon-like peptide-1 (GLP-1) receptor agonists, exenatide, lixisenatide, liraglutide, dulaglutide and semaglutide, are among the recent subcutaneous treatment options that provide better glycemic improvement and weight loss in patients with …

  8. Open Access 01-12-2023 | Exenatide | OriginalPaper

    Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study

    Cardiovascular (CV) disease remains the leading cause of mortality among people with diabetes, accounting for forty percent from coronary heart disease (CHD) [ 1 ]. Coronary revascularization is, together with optimal anti-ischemic therapy, the …

  9. 04-10-2023 | Exenatide | Online First

    Predictors of glycemic and weight responses to exenatide in patients with type 2 diabetes mellitus

    Type 2 diabetes mellitus (T2DM) is a metabolic disease characterised by hyperglycaemia. Without timely intervention and treatment, it may eventually bring about life-threatening microvascular and macrovascular complications [ 1 ]. Maintaining tight …

  10. Open Access 01-12-2023 | Insulin Glargine | OriginalPaper

    The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes

    The 2008 Food and Drug Administration (FDA) guidance requiring ascertainment of the cardiovascular safety of new glucose-lowering medications has launched an era in which the vascular implications of diabetes therapies are fundamental …

  11. Open Access 01-12-2022 | Exenatide | OriginalPaper

    Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become established as blood glucose-lowering therapies that should be considered in people with type 2 diabetes if glycemic targets are not met with lifestyle measures and metformin [ 1 ] …

  12. Open Access 01-12-2023 | Exenatide | OriginalPaper

    Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis

    Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of childbearing age and is associated with high androgen levels, oligomenorrhea or amenorrhea, anovulation, and polycystic morphology of the ovaries, according to …

  13. Open Access 01-12-2022 | Exenatide | OriginalPaper

    Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study

    Many new anti-diabetic medications for diabetes have been developed and marketed, including incretin glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), in the past two decades. It has been shown that GLP-1RAs reduce cardiovascular …

  14. 01-10-2022 | Metformin | News

    Exenatide

    Anaphylactic shock and scleroma: case report
  15. 01-01-2022 | Interstitial Nephritis | News

    Exenatide

    Acute interstitial nephritis: case report
  16. Open Access 13-08-2022 | Exenatide | OriginalPaper

    Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide

    The increasing prevalence and incidence of diabetes and its complications represent a global public health burden. According to data released by the International Diabetes Federation, there are 537 million diabetic adults aged 20–79 years old in …

  17. Open Access 01-12-2022 | Dapagliflozin | OriginalPaper

    Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

    Type 2 diabetes (T2D) is associated with cardiovascular (CV) morbidity and mortality, due to a combination of effects of hyperglycemia and frequently associated obesity, dyslipidemia and hypertension. In the last decades, two novel drug classes …

  18. 01-08-2021 | Panniculitis | News

    Exenatide

    Migratory panniculitis: case report
  19. 01-03-2021 | Famotidine | News

    Exenatide/metformin

    Allergic angioedema and gastrointestinal disorder: case report
  20. 01-01-2021 | Obesity | News

    Exenatide

    Urinary tract infections and obstipation following off-label use: case report

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.